PSR-Agility Wins Second Consecutive ROAR Award for “Best Orphan Drug CRO”
Continued recognition by industry and non-industry experts as unique partner in Orphan Drug Development
The PSR-Agility Orphan Drug Development partnership has for the second consecutive year been awarded “Best Orphan Drug Contract Research Organisation” in the Rare & Orphan Advocacy and Research (ROAR) Awards.
The ROAR Awards were announced during the 5th Annual World Orphan Drug Congress Europe. The 2014 awards recognize those who have done outstanding work in the rare disease field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of orphan drugs in the last year.
“Successively winning this award as the PSR-Agility Orphan Drug Development partnership is a clear appreciation by all stakeholders of our continued commitment in the rare disease community,” says Roger Legtenberg, CEO of PSR Orphan Experts. “Our efforts to provide crucial patient assistance by a range of services in order to lower the burden of rare disease patients in clinical trials, together with added infrastructure to be able to offer innovative patient recruitment solutions, have among others contributed considerably towards winning this award.”
“We’re thrilled that our commitment to innovating clinical development strategies for clients developing orphan drugs has been recognized consistently during our company’s first two years of partnership,” says Ellen Morgan, CEO of Agility. “Our vision for making a difference by dedicating ourselves to this specialty has become a reality.”
Other news from the department business & finance
